CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We have now added a new section called the "Assay History List" to the "At A Gla...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...